<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03044158</url>
  </required_header>
  <id_info>
    <org_study_id>R01HL130192</org_study_id>
    <secondary_id>PACTR201610001763265</secondary_id>
    <nct_id>NCT03044158</nct_id>
  </id_info>
  <brief_title>Xpert Omni Performance Evaluation</brief_title>
  <acronym>XPEL TB</acronym>
  <official_title>Xpert Omni Performance Evaluation for Linkage to Tuberculosis Care: The XPEL TB Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study proposes to conduct a pragmatic, parallel cluster-randomized trial with nested
      mixed methods, health economic and modeling studies to evaluate the effectiveness,
      implementation and costs of the intervention strategy relative to standard TB diagnostic
      evaluation at community health centers that are part of Xpert referral networks in Uganda.
      The effectiveness of the intervention strategy will be assessed using routine data collected
      as part of mandatory reporting to the Uganda NTLP on consecutive patients who present to
      participating health centers during the 2-year trial period and meet eligibility criteria.
      Selected patients and providers who provide informed consent will also be surveyed,
      interviewed, and/or participate in focus groups to identify reasons for its success or
      failure across study sites (Aim 2), and to collect relevant cost data for cost-effectiveness
      analyses (Aim 3).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim 1: To compare patient outcomes at health centers randomized to intervention vs.
      standard-of-care TB diagnostic evaluation strategies. The investigators will randomize 20-24
      community health centers to continue standard TB evaluation (routine microscopy plus referral
      of patients for Xpert testing per existing processes of care) or to implement the
      intervention strategy (onsite molecular testing with GeneXpert Omni; re-structuring
      clinic-level procedures to facilitate same-day TB diagnosis and treatment; and performance
      feedback). The investigators will compare reach and effectiveness based on the numbers and
      proportions of patients who complete TB testing, are found to have TB, and have treatment
      initiated over a 2-year period at each health center (approximate N=6500-8500 patients).

      Aim 2: To identify processes and contextual factors that influence the effectiveness and
      fidelity of the intervention TB diagnostic evaluation strategy. The investigators will use
      quantitative process metrics to assess the adoption and maintenance over time of the core
      components of the intervention strategy. The investigators will also collect quantitative and
      qualitative data to describe the fidelity of implementation of each component and
      faithfulness to our conceptual model.

      Aim 3: To compare the costs and epidemiological impact of intervention vs. standard-of-care
      TB diagnostic evaluation strategies The investigators will model the incremental costs and
      cost-effectiveness of intervention relative to standard-of-care TB diagnostic evaluation from
      the health system and patient perspective. The investigators will then construct an epidemic
      model of the population-level impact of the intervention strategy on TB incidence and
      mortality.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion treated for microbiologically-confirmed TB within two weeks of initial sputum submission</measure>
    <time_frame>Within 2 weeks of initial sputum submission</time_frame>
    <description>Effectiveness outcome. Numerator is number diagnosed and time-to-treatment within 14 days; denominator is number referred for TB testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number referred for TB testing</measure>
    <time_frame>Within 2 weeks of initial sputum submission</time_frame>
    <description>Effectiveness outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion completing testing</measure>
    <time_frame>Within 2 weeks of initial sputum submission</time_frame>
    <description>Effectiveness outcome. Numerator is number completing testing; denominator is number referred for testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number diagnosed with microbiologically-confirmed TB</measure>
    <time_frame>Within 2 weeks of initial sputum submission</time_frame>
    <description>Effectiveness outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number suspected/diagnosed with RIF-resistant TB</measure>
    <time_frame>Within 2 weeks of initial sputum submission</time_frame>
    <description>Effectiveness outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to microbiologically-confirmed TB</measure>
    <time_frame>Days from initial sputum submission to being diagnosed, up to 60 days.</time_frame>
    <description>Effectiveness outcome. Time-to-diagnosis if microbiologically-confirmed TB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number treated for TB</measure>
    <time_frame>Within 2 weeks of initial sputum submission</time_frame>
    <description>Effectiveness outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients enrolled</measure>
    <time_frame>Within 2 weeks of initial sputum submission</time_frame>
    <description>Effectiveness outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number diagnosed and treated for microbiologically-confirmed TB</measure>
    <time_frame>Within 2 weeks of initial sputum submission</time_frame>
    <description>Effectiveness outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-treatment of microbiologically-confirmed TB</measure>
    <time_frame>Days from initial health center visit to initiation of treatment if diagnosed, up to 1 year.</time_frame>
    <description>Effectiveness outcome. Time-to-treatment if microbiologically-confirmed TB and treated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number diagnosed AND completing treatment</measure>
    <time_frame>Days from initial health center visit to treatment outcome, up to 2 years.</time_frame>
    <description>Effectiveness outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number who died within 6 months</measure>
    <time_frame>Days from initial health center visit to treatment outcome, up to 6 months.</time_frame>
    <description>Effectiveness outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8000</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <condition>Rifampicin Resistant Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Onsite ZN or LED fluorescence microscopy + hub-based GeneXpert testing per existing protocols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Onsite molecular testing for TB with GeneXpert Omni + process redesign to facilitate same-day TB diagnosis and treatment + performance feedback</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GeneXpert Omni</intervention_name>
    <description>Onsite molecular testing with GeneXpert Omni as a replacement for microscopy</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Omni</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Process re-design</intervention_name>
    <description>Research and Uganda NTLP staff will engage health center staff in a discussion of how to re-organize clinical, laboratory and pharmacy services to enable same-day TB diagnosis and treatment.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Performance Feedback</intervention_name>
    <description>Feedback of TB diagnostic evaluation quality indicators to health center staff</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Site-level: Use standard (multi-day) sputum smear microscopy as the primary method of
             TB diagnosis

          -  Site-level: Participate in NTP-sponsored external quality assurance (EQA) for sputum
             smear microscopy

          -  Site-level: Send samples to a district or regional hospital/health center for Xpert
             testing

          -  Patient-level: Initiate evaluation for active TB at a study health center

        Exclusion Criteria:

          -  Site-level: Do not agree to be randomized to standard-of-care vs. intervention arms

          -  Site-level: Perform sputum smear examination on &lt;150 patients per year (based on 2015
             data)

          -  Site-level: Diagnose &lt;15 smear-positive TB cases per year (based on 2015 data)

          -  Patient-level: Have sputum collected for monitoring of response to anti-TB therapy

          -  Patient-level: Have sputum collected as part of active, community-based case finding
             (e.g., contact tracing, community outreach campaign)

          -  Patient-level: Referred to a study health center for TB treatment after a diagnosis is
             established elsewhere

          -  Patient-level: Started on TB treatment for extra-pulmonary TB only
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adithya Cattamanchi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adithya Cattamanchi, MD</last_name>
    <phone>+1-415-206-5489</phone>
    <email>adithya.cattamanchi@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ngogwe Health Center III</name>
      <address>
        <city>Buikwe</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Francis Njeru Health Center III</name>
      <address>
        <city>Buikwe</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Busana Health Center III</name>
      <address>
        <city>Busana</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Busesa Health Center IV</name>
      <address>
        <city>Busesa</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Buwama Health Center III</name>
      <address>
        <city>Buwama</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanoni Health Center III</name>
      <address>
        <city>Gombe</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Iganga TC</name>
      <address>
        <city>Iganga</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kalagala Health Center IV</name>
      <address>
        <city>Kalagala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kangulumira Health Center IV</name>
      <address>
        <city>Kangulumira</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kasangati Health Center IV</name>
      <address>
        <city>Kasangati</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bukomero Health Center IV</name>
      <address>
        <city>Katera</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bale Health Center IV</name>
      <address>
        <city>Kayunga</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kiganda Health Center IV</name>
      <address>
        <city>Kiganda</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kira Health Center III</name>
      <address>
        <city>Kira</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyanamukaka Health Center IV</name>
      <address>
        <city>Kyanamukaka</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lugasa Health Center III</name>
      <address>
        <city>Lugala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayuge Health Center III</name>
      <address>
        <city>Mayuge</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mwera Health Center IV</name>
      <address>
        <city>Mityana</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kojja Health Center IV</name>
      <address>
        <city>Mukono</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nakasongola Health Center IV</name>
      <address>
        <city>Nakasongola</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Namungalwe Health Center III</name>
      <address>
        <city>Namungalwe</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nankandulo Health Center IV</name>
      <address>
        <city>Nankandulo</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ndejje Health Center IV</name>
      <address>
        <city>Ndeje</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wakiso Health Center IV</name>
      <address>
        <city>Wakiso</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <reference>
    <citation>MacPherson P, Houben RM, Glynn JR, Corbett EL, Kranzer K. Pre-treatment loss to follow-up in tuberculosis patients in low- and lower-middle-income countries and high-burden countries: a systematic review and meta-analysis. Bull World Health Organ. 2014 Feb 1;92(2):126-38. doi: 10.2471/BLT.13.124800. Epub 2013 Nov 22. Review.</citation>
    <PMID>24623906</PMID>
  </reference>
  <reference>
    <citation>Cattamanchi A, Dowdy DW, Davis JL, Worodria W, Yoo S, Joloba M, Matovu J, Hopewell PC, Huang L. Sensitivity of direct versus concentrated sputum smear microscopy in HIV-infected patients suspected of having pulmonary tuberculosis. BMC Infect Dis. 2009 May 6;9:53. doi: 10.1186/1471-2334-9-53.</citation>
    <PMID>19419537</PMID>
  </reference>
  <reference>
    <citation>Chihota VN, Ginindza S, McCarthy K, Grant AD, Churchyard G, Fielding K. Missed Opportunities for TB Investigation in Primary Care Clinics in South Africa: Experience from the XTEND Trial. PLoS One. 2015 Sep 18;10(9):e0138149. doi: 10.1371/journal.pone.0138149. eCollection 2015.</citation>
    <PMID>26383102</PMID>
  </reference>
  <reference>
    <citation>Davis J, Katamba A, Vasquez J, Crawford E, Sserwanga A, Kakeeto S, Kizito F, Dorsey G, den Boon S, Vittinghoff E, Huang L, Adatu F, Kamya MR, Hopewell PC, Cattamanchi A. Evaluating tuberculosis case detection via real-time monitoring of tuberculosis diagnostic services. Am J Respir Crit Care Med. 2011 Aug 1;184(3):362-7. doi: 10.1164/rccm.201012-1984OC. Epub 2011 Mar 11.</citation>
    <PMID>21471088</PMID>
  </reference>
  <reference>
    <citation>Aspler A, Menzies D, Oxlade O, Banda J, Mwenge L, Godfrey-Faussett P, Ayles H. Cost of tuberculosis diagnosis and treatment from the patient perspective in Lusaka, Zambia. Int J Tuberc Lung Dis. 2008 Aug;12(8):928-35.</citation>
    <PMID>18647453</PMID>
  </reference>
  <reference>
    <citation>Kemp JR, Mann G, Simwaka BN, Salaniponi FM, Squire SB. Can Malawi's poor afford free tuberculosis services? Patient and household costs associated with a tuberculosis diagnosis in Lilongwe. Bull World Health Organ. 2007 Aug;85(8):580-5.</citation>
    <PMID>17768515</PMID>
  </reference>
  <reference>
    <citation>Simwaka BN, Bello G, Banda H, Chimzizi R, Squire BS, Theobald SJ. The Malawi National Tuberculosis Programme: an equity analysis. Int J Equity Health. 2007 Dec 31;6:24. doi: 10.1186/1475-9276-6-24.</citation>
    <PMID>18163918</PMID>
  </reference>
  <reference>
    <citation>Botha E, den Boon S, Lawrence KA, Reuter H, Verver S, Lombard CJ, Dye C, Enarson DA, Beyers N. From suspect to patient: tuberculosis diagnosis and treatment initiation in health facilities in South Africa. Int J Tuberc Lung Dis. 2008 Aug;12(8):936-41.</citation>
    <PMID>18647454</PMID>
  </reference>
  <reference>
    <citation>Ouyang H, Chepote F, Gilman RH, Moore DA. Failure to complete the TB diagnostic algorithm in urban Perú: a study of contributing factors. Trop Doct. 2005 Apr;35(2):120-1.</citation>
    <PMID>15970047</PMID>
  </reference>
  <reference>
    <citation>Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014 Jan 21;(1):CD009593. doi: 10.1002/14651858.CD009593.pub3. Review.</citation>
    <PMID>24448973</PMID>
  </reference>
  <reference>
    <citation>Dowdy DW, Cattamanchi A, Steingart KR, Pai M. Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis. PLoS Med. 2011 Jul;8(7):e1001063. doi: 10.1371/journal.pmed.1001063. Epub 2011 Jul 26.</citation>
    <PMID>21814496</PMID>
  </reference>
  <reference>
    <citation>Keeler E, Perkins MD, Small P, Hanson C, Reed S, Cunningham J, Aledort JE, Hillborne L, Rafael ME, Girosi F, Dye C. Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature. 2006 Nov 23;444 Suppl 1:49-57.</citation>
    <PMID>17159894</PMID>
  </reference>
  <reference>
    <citation>Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, Bara W, Mungofa S, Pai M, Hoelscher M, Dowdy D, Pym A, Mwaba P, Mason P, Peter J, Dheda K; TB-NEAT team. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2014 Feb 1;383(9915):424-35. doi: 10.1016/S0140-6736(13)62073-5. Epub 2013 Oct 28.</citation>
    <PMID>24176144</PMID>
  </reference>
  <reference>
    <citation>Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999 Sep;89(9):1322-7. Review.</citation>
    <PMID>10474547</PMID>
  </reference>
  <reference>
    <citation>Godin G, Bélanger-Gravel A, Eccles M, Grimshaw J. Healthcare professionals' intentions and behaviours: a systematic review of studies based on social cognitive theories. Implement Sci. 2008 Jul 16;3:36. doi: 10.1186/1748-5908-3-36.</citation>
    <PMID>18631386</PMID>
  </reference>
  <reference>
    <citation>Davis DA, Thomson MA, Oxman AD, Haynes RB. Evidence for the effectiveness of CME. A review of 50 randomized controlled trials. JAMA. 1992 Sep 2;268(9):1111-7.</citation>
    <PMID>1501333</PMID>
  </reference>
  <reference>
    <citation>Cattamanchi A, Miller CR, Tapley A, Haguma P, Ochom E, Ackerman S, Davis JL, Katamba A, Handley MA. Health worker perspectives on barriers to delivery of routine tuberculosis diagnostic evaluation services in Uganda: a qualitative study to guide clinic-based interventions. BMC Health Serv Res. 2015 Jan 22;15:10. doi: 10.1186/s12913-014-0668-0.</citation>
    <PMID>25609495</PMID>
  </reference>
  <reference>
    <citation>Ivers N, Jamtvedt G, Flottorp S, Young JM, Odgaard-Jensen J, French SD, O'Brien MA, Johansen M, Grimshaw J, Oxman AD. Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev. 2012 Jun 13;(6):CD000259. doi: 10.1002/14651858.CD000259.pub3. Review.</citation>
    <PMID>22696318</PMID>
  </reference>
  <reference>
    <citation>Grogan S, Conner M, Norman P, Willits D, Porter I. Validation of a questionnaire measuring patient satisfaction with general practitioner services. Qual Health Care. 2000 Dec;9(4):210-5.</citation>
    <PMID>11101705</PMID>
  </reference>
  <reference>
    <citation>Nabbuye-Sekandi J, Makumbi FE, Kasangaki A, Kizza IB, Tugumisirize J, Nshimye E, Mbabali S, Peters DH. Patient satisfaction with services in outpatient clinics at Mulago hospital, Uganda. Int J Qual Health Care. 2011 Oct;23(5):516-23. doi: 10.1093/intqhc/mzr040. Epub 2011 Jul 19.</citation>
    <PMID>21775313</PMID>
  </reference>
  <reference>
    <citation>Ivers NM, Halperin IJ, Barnsley J, Grimshaw JM, Shah BR, Tu K, Upshur R, Zwarenstein M. Allocation techniques for balance at baseline in cluster randomized trials: a methodological review. Trials. 2012 Aug 1;13:120. doi: 10.1186/1745-6215-13-120. Review.</citation>
    <PMID>22853820</PMID>
  </reference>
  <reference>
    <citation>Sismanidis C, Moulton LH, Ayles H, Fielding K, Schaap A, Beyers N, Bond G, Godfrey-Faussett P, Hayes R. Restricted randomization of ZAMSTAR: a 2 x 2 factorial cluster randomized trial. Clin Trials. 2008;5(4):316-27. doi: 10.1177/1740774508094747.</citation>
    <PMID>18697846</PMID>
  </reference>
  <reference>
    <citation>Sandelowski M, Leeman J. Writing usable qualitative health research findings. Qual Health Res. 2012 Oct;22(10):1404-13. doi: 10.1177/1049732312450368. Epub 2012 Jun 28.</citation>
    <PMID>22745362</PMID>
  </reference>
  <reference>
    <citation>Sandelowski MJ. Justifying qualitative research. Res Nurs Health. 2008 Jun;31(3):193-5. doi: 10.1002/nur.20272.</citation>
    <PMID>18288640</PMID>
  </reference>
  <reference>
    <citation>Voils CI, Sandelowski M, Barroso J, Hasselblad V. Making Sense of Qualitative and Quantitative Findings in Mixed Research Synthesis Studies. Field methods. 2008;20(1):3-25.</citation>
    <PMID>18677415</PMID>
  </reference>
  <reference>
    <citation>Salje H, Andrews JR, Deo S, Satyanarayana S, Sun AY, Pai M, Dowdy DW. The importance of implementation strategy in scaling up Xpert MTB/RIF for diagnosis of tuberculosis in the Indian health-care system: a transmission model. PLoS Med. 2014 Jul 15;11(7):e1001674. doi: 10.1371/journal.pmed.1001674. eCollection 2014 Jul.</citation>
    <PMID>25025235</PMID>
  </reference>
  <reference>
    <citation>Dowdy DW, Basu S, Andrews JR. Is passive diagnosis enough? The impact of subclinical disease on diagnostic strategies for tuberculosis. Am J Respir Crit Care Med. 2013 Mar 1;187(5):543-51. doi: 10.1164/rccm.201207-1217OC. Epub 2012 Dec 21.</citation>
    <PMID>23262515</PMID>
  </reference>
  <reference>
    <citation>Sun AY, Denkinger CM, Dowdy DW. The impact of novel tests for tuberculosis depends on the diagnostic cascade. Eur Respir J. 2014 Nov;44(5):1366-9. doi: 10.1183/09031936.00111014. Epub 2014 Sep 3.</citation>
    <PMID>25186263</PMID>
  </reference>
  <reference>
    <citation>Chandrasekaran V, Ramachandran R, Cunningham J, Balasubramaniun R, Thomas A, Sudha G, et al. Factors leading to tuberculosis diagnostic drop-out and delayed treatment initiation in Chennai, India. Int J Tuberc Lung Dis. 2005;9:172.</citation>
  </reference>
  <reference>
    <citation>Den Boon S, Semitala F, Cattamanchi A, Walter N, Worodria W, Joloba M, Huang L, Davis JL. Impact of patient drop-out on the effective sensitivity of smear microscopy strategies. Am J Respir Crit Care Med 2010;181:A2258.</citation>
  </reference>
  <reference>
    <citation>Miller C, Haguma P, Ochom E, Ross J, Davis JL, Cattamanchi A, Katamba A. Costs associated with tuberculosis evaluation in rural Uganda. 43rd Union World Conference on Lung Health; Kuala Lumpur, Malaysia 2012.</citation>
  </reference>
  <reference>
    <citation>WHO. Global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva, Switzerland: World Health Organization, 2013 EB134/12.</citation>
  </reference>
  <reference>
    <citation>WHO. WHO monitoring of Xpert MTB/RIF roll-out. Available at: http://www.who.int/tb/areas-of-work/laboratory/mtb-rif-rollout/en/ [cited 2015 January 15].</citation>
  </reference>
  <reference>
    <citation>Churchyard GJ, on behalf of the Xtend study team. Xpert MTB/RIF vs microscopy as the first line TB test in South Africa: mortality, yield, initial loss to follow up and proportion treated. The Xtend Study. Conference on Retroviruses and Opportunistic Infections; Boston, USA: Available at: http://www.stoptb.org/wg/gli/assets/documents/M6/Churchyard%20-%20XTEND%20study.pdf; 2014.</citation>
  </reference>
  <reference>
    <citation>Cepheid. GeneXpert Omni: The True Point of Care Molecular Diagnostic System: Cepheid Inc; 2015. Available from: http://www.cepheid.com/us/genexpert-omni.</citation>
  </reference>
  <reference>
    <citation>Ajzen I. The theory of planned behavior. Organizational Behavior and Human Decision Processes. 1991;50:179-211.</citation>
  </reference>
  <reference>
    <citation>Green LW, Krueter M. Health Program Planning - An Educational and Ecological Approach. 4th ed. Philadelphia, USA: McGraw-Hill; 2005.</citation>
  </reference>
  <reference>
    <citation>Hayes RJ, Moulton LH. Cluster Randomized Trials. Boca Raton, Florida, USA: CRC Press; 2009.</citation>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2017</study_first_submitted>
  <study_first_submitted_qc>February 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2017</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tuberculosis</keyword>
  <keyword>implementation science</keyword>
  <keyword>point-of-care</keyword>
  <keyword>diagnostics</keyword>
  <keyword>GeneXpert</keyword>
  <keyword>Uganda</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Provided upon request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

